NDNerketa N. L. Damiba

Nerketa N. L. Damiba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nerketa N. L. Damiba has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tuberculous Meningitis Alters the Proteomic Landscape of Brain-Derived Extracellular Vesicles

    by Blanca V. Rodriguez, Nerketa N. L. Damiba, Harshita Tak, Nicole Beaubien, Daisy Puca, D. Brian Foster, Samarjit Das, Elizabeth W. Tucker

    Tuberculous meningitis (TB meningitis), the deadliest form of Mycobacterium tuberculosis infection, causes devastating mortality and severe neurological disability despite standard therapy. Brain injury and microglial activation are major determinants of outcome, yet the molecular mechanisms linking infection, inflammation, and neuronal injury remain poorly understood. Extracellular vesicles (EVs), critical mediators of cell-to-cell communication, have been investigated in pulmonary TB, but their role in TB meningitis remains unexplored. We used a young New Zealand White rabbit model of TB meningitis to isolate and characterize brain-derived EVs from infected and uninfected rabbits employing nanoflow cytometry, transmission electron microscopy, proteomic profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS), and bioinformatic analysis of pathways, cell-type enrichment, and protein-protein interaction networks (DAVID, Enrichr, and STRING databases). EV recovery from flash-frozen brain tissue proved feasible, enabling future studies using biobanked samples. M. tuberculosis infection increased EV release in brain tissue and induced a selective proteomic shift characterized by enrichment of proteins associated with TB host defense, microglial activation, and stress-response pathways, coupled with a reduced representation of neuronal and neuroprotective EV-associated proteins. These findings suggest that infection reprograms the brain EV proteome toward inflammatory and injury-associated pathways. Collectively, this study provides the first comprehensive proteomic characterization of brain-derived EVs in TB meningitis and establishes a foundational atlas of EV-associated proteins altered during infection. These findings identify candidate proteins for future biomarker validation in accessible biofluids (e.g., plasma and CSF) and provide a framework for generating hypotheses about EV-mediated host–pathogen interactions in the CNS during TB meningitis.

  • Open Access

    Dendrimer-Conjugated Glutamine Antagonist, D-TTM020, Ameliorates Brain Immune Dysregulation and Improves Neurobehavioral Deficits in the Mecp2-Deficient Mouse Model

    by Preeti Vyas, Elizabeth Smith Khoury, Nirnath Sah, Anjali Sharma, Javier Allende Labastida, Elizabeth L. Wilkinson, Kathleen Lac, Nerketa N. L. Damiba, Amanda Fowler, Jinhuan Liu, et al.

    Rett Syndrome (RTT) is a neurodevelopmental disorder characterized by mutations in the MeCP2 gene, predominantly affecting females. Recent work with MeCP2-deficient mouse models showed a significant role in glutamatergic transmission, specifically microglia-produced glutamate and glutaminase upregulation, in RTT pathology. The glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) is a potent glutaminase inhibitor; however, its use is limited due to systemic toxicities arising from its non-specific inhibition of glutamine-utilizing reactions. In this work, we determined whether dendrimer conjugation of a DON analog, TTM020 (or D-TTM020), results in targeted microglial glutaminase inhibition and behavioral changes in Mecp2 KO and heterozygous mice upon systemic administration. D-TTM020 at 1 mg/kg (drug basis) selectively and significantly inhibits glutaminase enzyme activity in the microglia of Mecp2 KO mice. Biweekly systemic treatment with 1 mg/kg of D-TTM020 improved the neurobehavioral phenotype in symptomatic Mecp2 KO and het mice. D-TTM020 also restored long-term retrieval of conditioned fear memory and improved cue responses during fear extinction after 8 weeks of treatment in symptomatic Mecp2 het mice. Our data indicate that selectively targeting glutamine metabolism in dysregulated glia using dendrimers represents a promising strategy that may offer a therapeutic approach for addressing glutamate dysregulation in RTT.